Table. 4 Summary of clinical trials combining epigenetic inhibitors with other treatment modalities.
From: Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies
Drug | Disease | NCT Number | Interventions | Phase |
|---|---|---|---|---|
HDACi | Relapsed/refractory classical Hodgkin lymphoma | NCT06393361 | 1. Chidamide; Decitabine; Anti-PD-1 Antibody 2. Brentuximab Vedotin, anti-PD-1 antibody. | II |
NCT06563778 | 1. Chidamide; Decitabine; Anti-PD-1 Antibody 2. Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody | II | ||
Hodgkin Lymphoma | NCT04514081 | 1. Chidamide; Decitabine; Camrelizumab 2. Decitabine+Camrelizumab | II | |
NCT04233294 | Chidamide; Camrelizumab; Decitabine | II | ||
Non-Hodgkin Lymphoma | NCT04337606 | Chidamide; Decitabine; Camrelizumab | I/II | |
1. Relapsed/Refractory Non-Hodgkin Lymphoma 2. Advanced Solid Tumors | NCT05320640 | Chidamide; Decitabine; Immune checkpoint inhibitors (anti-PD-1/PD-L1/CTLA4 antibodies) | I/II | |
Neuroendocrine Tumors | NCT05113355 | Chidamide; Sintilimab | II | |
Multiple Advanced Cancers | NCT04708470 | Bintrafusp Alfa; PDS01ADC; Entinostat | I/II | |
EZH2i | Multiple Advanced Cancers | NCT06022757 | XNW5004; KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection | Ib/II |
HR+/HER2- endocrine-resistant advanced breast cancer | NCT04355858 | SHR3162; SHR2554 | II | |
1. Advanced Solid Tumor 2. Lymphoma | NCT04407741 | 1. SHR2554 and SHR1701 2. SHR1701 | I/II | |
Follicular Lymphoma | NCT05551936 | Bendamustine; Rituximab; Tazemetostat | I/II | |
Recurrent Ovarian Cancer | NCT05942300 | CPI-0209; Carboplatin | I | |
Metastatic Castration-Resistant Prostate Cancer | NCT06629779 | PF-06821497; Placebo; Enzalutamide | III | |
NCT06551324 | PF-06821497; Docetaxel; Enzalutamide | III | ||
Follicular Lymphoma | NCT04224493 | Tazemetostat; Lenalidomide; Rituximab | Ib/III | |
Hepatocellular Carcinoma | NCT06294548 | Valemetostat; Atezolizumab; Bevacizumab | Ib/II | |
Metastatic Melanoma | NCT04557956 | Tazemetostat; Dabrafenib; Trametinib | I/II | |
CDK7i | Advanced Cancer | NCT05394103 | Q901; KEYTRUDA® (pembrolizumab) | I/II |
SMARCA2i | Advanced Solid Tumor | NCT05639751 | PRT3789; Docetaxel | I |
NCT06682806 | PRT3789; pembrolizumab | II |
